BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2021 12:05:59 PM | Browse: 718 | Download: 1966
 |
Received |
|
2020-11-26 19:48 |
|
Peer-Review Started |
|
2020-11-26 19:48 |
|
First Decision by Editorial Office Director |
|
2020-12-11 18:57 |
|
Return for Revision |
|
2020-12-11 18:57 |
|
Revised |
|
2021-01-02 09:54 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-01-28 06:17 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-03-01 16:15 |
|
Articles in Press |
|
2021-03-01 16:15 |
|
Edit the Manuscript by Language Editor |
|
2021-03-06 23:13 |
|
Typeset the Manuscript |
|
2021-03-10 05:25 |
|
Publish the Manuscript Online |
|
2021-03-11 12:05 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Overview of recent advances in metastatic triple negative breast cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
David O'Reilly, Maha Al Sendi and Catherine M Kelly |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
David O'Reilly, MBChB, MRCP, Academic Fellow, Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 1, Ireland. oreilld8@tcd.ie |
| Key Words |
Triple negative breast cancer; Immunotherapy; Poly (adenosine diphosphate-ribose) polymerase inhibitors; Breast cancer |
| Core Tip |
Despite recent advances, chemotherapy remains integral to the management of advanced triple negative breast cancer. Immunotherapy and poly (adenosine diphosphate-ribose) polymerase inhibitors have shown much promise but have yet to demonstrate a proven overall survival benefit in this disease. Antibody drug conjugates and other targeted therapies may ultimately prove to be the next frontier in treating this illness. |
| Publish Date |
2021-03-11 12:05 |
| Citation |
O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021; 12(3): 164-182 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i3/164.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i3.164 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
